Skip to main content

Max Planck Partners with Evotec Technologies and Definiens to Develop High Throughput RNAi and Imaging Platform

NEW YORK, Sept. 19 (GenomeWeb News) - The Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany announced today that it is teaming up with German companies Evotec Technologies of Hamburg and Definiens of Munich to develop a new platform for high throughput RNAi and cell-based screening and image analysis.

 

The partnership is part of "biosaxony," a Saxon biotech initiative endorsed by the state government of Saxony, Germany.

 

MPI-CBG was the first institute to publish a genome-scale analysis using RNAi in C. elegans, and will now provide the assays, location and laboratory facilities for the study. The Institute will use Evotec's confocal optics-based fluorescent imaging platform Opera to collect data and Definiens' object-oriented image analysis platform called Cognition Network Technology to analyze the data.

 

The group hopes to commercialize the methods they develop for industry use.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.